Oncotarget is an intensive scientific journal that reports the findings of researches on various cases through Impact Journal. One recent scientific conclusion indicated that breast cancer cells are highly receptive to hormonal therapy. Oncotarget’s report detailed the drugs that practitioners can distribute for specific breast cancer types.

In the article, breast cancer cells were reported to contain a high reception to the hormones estrogen and progesterone. The most severe cancer type, TNBC, affects approximately 15 percent of all breast cancer victims. The severity of the case is aggravated by the cells’ inability to react positively to hormonal therapy. Their research was progressed farther by scientists at the Mayo Clinic, who sough to understand the operation of molecules so as to develop effective treatment. Oncotarget’s report states that Dr.Hawse of Mayo Clinic concluded that a cell cycle protein caused the non-receptive nature of cells in TNBC patients. The studies verified that cancer cells containing ERß have a high rate of redemption than the Era. Mayo Clinic plans to conduct farther analysis on animals to create an effectual treatment plan. Learn more about Oncotarget at researchgate.net

Oncotarget integrates the effort of highly revered scientists to output detailed and informative articles to its subscribers. It has recently began publishing with PubMed, and plans to increase its indexing. Since the conception of the contract, Oncotarget has publicized 7 volumes, and is set to launch the 8th, which is currently under procession by the National Library of Medicine.

Oncotarget has a strong resolve to meet the intellectual demands of the 21st century scientific community. They have secured a publishing platform with PubMed, ISI/Web of Science and EMBASE. Oncotarget has become the first scientific newsletter to have a space of PubMed, shortly after the launch of its online portal.

Read: http://markets.businessinsider.com/news/stocks/Oncotarget-Now-Publishing-Two-Issues-a-Week-Available-in-PubMed-and-Other-High-Profile-Scientific-Research-Indexes-and-Archives-1002382405

The journal’s team of editors and administrators state that their primary role is to enhance their reports to meet the quality demands of expert scientists. The office managing the legal affairs of the journal stated that they concentrate on providing scholar-based reading to subscribers with varied intrests in science. Oncotarget’s major audience consists of other scientists who consider the journal a trustworthy source to advance their research. Check the journal at SCImago Journal & Country Rank.

Source – http://www.wmcactionnews5.com/story/36849680/oncotarget-researchers-identify-potential-therapeutic-target-in-aggressive-breast-cancer-cells